ES2725948T3 - Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas - Google Patents

Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas Download PDF

Info

Publication number
ES2725948T3
ES2725948T3 ES15753219T ES15753219T ES2725948T3 ES 2725948 T3 ES2725948 T3 ES 2725948T3 ES 15753219 T ES15753219 T ES 15753219T ES 15753219 T ES15753219 T ES 15753219T ES 2725948 T3 ES2725948 T3 ES 2725948T3
Authority
ES
Spain
Prior art keywords
oligonucleotides
liposomal
nanostructure
antigen
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15753219T
Other languages
English (en)
Spanish (es)
Inventor
Aleksandar Filip Radovic-Moreno
Richard Kang
Subbarao Nallagatla
Christopher C Mader
Sergei Gryaznov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exicure Inc
Original Assignee
Exicure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exicure Inc filed Critical Exicure Inc
Application granted granted Critical
Publication of ES2725948T3 publication Critical patent/ES2725948T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES15753219T 2014-06-04 2015-06-04 Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas Active ES2725948T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462007528P 2014-06-04 2014-06-04
PCT/US2015/034226 WO2015187966A1 (en) 2014-06-04 2015-06-04 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Publications (1)

Publication Number Publication Date
ES2725948T3 true ES2725948T3 (es) 2019-09-30

Family

ID=53887176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15753219T Active ES2725948T3 (es) 2014-06-04 2015-06-04 Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas

Country Status (11)

Country Link
US (3) US10434064B2 (enExample)
EP (2) EP3164113B1 (enExample)
JP (1) JP6581604B2 (enExample)
KR (1) KR102290205B1 (enExample)
CN (1) CN106535876B (enExample)
AU (1) AU2015269412B2 (enExample)
CA (1) CA2953216C (enExample)
ES (1) ES2725948T3 (enExample)
PL (1) PL3164113T3 (enExample)
TR (1) TR201908550T4 (enExample)
WO (1) WO2015187966A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
MX389323B (es) 2013-12-03 2025-03-20 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗ｔｎｆ化合物
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
EP3247796A4 (en) 2015-01-14 2018-07-11 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2016134104A1 (en) * 2015-02-18 2016-08-25 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017136467A1 (en) * 2016-02-01 2017-08-10 Exicure, Inc. Surface functionaliztion of liposomes and liposomal spherical nucleic acids (snas)
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
CA3023445A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Spherical nucleic acid tlr9 agonists
CA3023449A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Tlr9-targeted spherical nucleic acids having potent antitumor activity
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2019184991A1 (zh) * 2018-03-29 2019-10-03 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
MA49023A (fr) * 2017-03-29 2020-02-05 Inst Basic Medical Sciences Cams Application d'un composé ou d'un extrait de médecine chinoise traditionnelle dans la préparation d'un agent d'administration d'acide nucléique et produits apparentés correspondants
CN116082391A (zh) * 2017-03-29 2023-05-09 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
US20200248183A1 (en) * 2017-04-03 2020-08-06 Subbarao Nallagatla Tlr9-targeted spherical nucleic acids having potent antitumor activity
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) * 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
RU2020117611A (ru) * 2017-11-02 2021-12-02 Янссен Байофарма, Инк. Олигонуклеотидные конструкты и их применение
US20200384104A1 (en) * 2017-12-15 2020-12-10 Northwestern University Structure-Function Relationships in the Development of Immunotherapeutic Agents
SG11202010910QA (en) 2018-05-07 2020-12-30 Alnylam Pharmaceuticals Inc Extrahepatic delivery
US20230330219A1 (en) * 2019-01-24 2023-10-19 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for programming immune stimulation
US20220088059A1 (en) * 2019-02-12 2022-03-24 Exicure Operating Company Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
CN110559263B (zh) * 2019-10-10 2021-05-14 中国海洋大学 一种△5-胆甾硫酸基类化合物脂质体及其制备方法
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20210220454A1 (en) * 2020-01-22 2021-07-22 Northwestern University Design of immunostimulatory protein-core spherical nucleic acids
AU2021254270A1 (en) * 2020-04-10 2022-11-24 Northwestern University Oxidized tumor cell lysates encapsulated in liposomal spherical nucleic acids as potent cancer immunotherapeutics
WO2022192038A1 (en) * 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
CN118903116B (zh) * 2023-05-08 2025-08-12 中山大学 溶血磷脂酸抑制剂在制备抑制prrsv复制药物中的应用
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Family Cites Families (486)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5541308A (en) 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE3851889T2 (de) 1987-06-24 1995-04-13 Florey Howard Inst Nukleosid-derivate.
AU630076B2 (en) 1987-09-21 1992-10-22 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
JP3019994B2 (ja) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DE69033495T2 (de) 1989-10-24 2000-07-20 Isis Pharmaceuticals, Inc. 2'-modifizierte nukleotide
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
KR100211552B1 (ko) 1990-08-03 1999-08-02 디. 꼬쉬 유전자 발현 억제용 화합물 및 방법
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
FR2677272B1 (fr) 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
ATE239484T1 (de) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
EP0637384B1 (en) 1992-04-22 1996-10-02 Ecole Polytechnique Federale De Lausanne Lipid membrane sensors
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
WO1994001550A1 (en) 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
CA2159631A1 (en) 1993-03-30 1994-10-13 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
WO1994022891A1 (en) 1993-03-31 1994-10-13 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
WO1995006731A2 (en) 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
KR100386337B1 (ko) 1993-12-09 2004-03-24 토마스 제퍼슨 대학교 진핵세포에서부위-특이적돌연변이를위한화합물과그방법
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
DE69638099D1 (de) 1995-05-04 2010-01-28 Gilead Sciences Inc Nukleinsäureligand-komplexe
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
AU3379597A (en) 1996-06-19 1998-01-07 Hybridon, Inc. Modulation of tetraplex formation by chemical modifications of a g4-containing oligonucleotide
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
EP1818417B1 (en) 1996-07-29 2014-02-12 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US20020172953A1 (en) 1996-07-29 2002-11-21 Mirkin Chad A. Movement of biomolecule-coated nanoparticles in an electric field
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
EP0856579A1 (en) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
KR100414936B1 (ko) 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6194328B1 (en) 1998-12-09 2001-02-27 Advanced Micro Devices, Inc. H2 diffusion barrier formation by nitrogen incorporation in oxide layer
WO2000042188A2 (en) 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP2003503699A (ja) 1999-06-25 2003-01-28 ナノスフェアー インコーポレイテッド オリゴヌクレオチドが付着しているナノ粒子およびその利用法
CA2377747C (en) 1999-07-08 2009-09-29 Cap Biotechnology, Inc. Calcium-containing structures and methods of making and using the same
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US6677153B2 (en) 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
US20030181412A1 (en) 1999-12-21 2003-09-25 Ingeneus Corporation Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses
IL150476A0 (en) 1999-12-30 2002-12-01 Aventis Pharma Sa Compositions comprising nucleic acids incorporated in bilaminar mineral particles
JP2004501340A (ja) 2000-01-13 2004-01-15 ナノスフェアー　インコーポレイテッド オリゴヌクレオチドを付着させたナノ粒子とその使用方法
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2402955C (en) 2000-03-28 2010-03-09 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
EP1267618A1 (en) 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
AU2002225670B2 (en) 2000-11-20 2006-05-11 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
DE10065475A1 (de) 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
US20060019917A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
WO2002096262A2 (en) 2001-05-25 2002-12-05 Northwestern University Non-alloying core shell nanoparticles
KR100904954B1 (ko) 2001-05-30 2009-06-26 더 스크립스 리서치 인스티튜트 핵산용 전달 시스템
AU2002345847B2 (en) 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP1990040A1 (en) 2001-07-10 2008-11-12 North Carolina State University Nanoparticle delivery vehicle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
EP1513859B1 (en) 2002-05-30 2010-07-14 Memorial Sloan-Kettering Cancer Center Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7884083B2 (en) 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1575977E (pt) 2002-12-23 2009-12-15 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US20060105343A1 (en) 2003-01-09 2006-05-18 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
CA2512484A1 (en) 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
JP2004315433A (ja) 2003-04-16 2004-11-11 Woong-Shick Ahn 乳頭腫ウィルス抗原蛋白質及びＣｐＧ−オリゴデオキシヌクレオチドを含む乳頭腫ウィルス誘発疾患の予防又は治療用薬剤学的組成物
JP2006528697A (ja) 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
EP2371834B1 (en) 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
US20050096263A1 (en) 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
CA2527102A1 (en) 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
KR101126030B1 (ko) 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
US20080057128A1 (en) 2003-07-18 2008-03-06 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US6979738B2 (en) 2003-10-22 2005-12-27 Academia Sinica Quadruplex stabilizer
BRPI0416079A (pt) 2003-10-30 2007-01-02 Coley Pharm Gmbh análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
EP1699814A4 (en) 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
US8389707B2 (en) 2004-02-26 2013-03-05 Bio-Rad Laboratories Inc. Oligonucleotides related to lipid membrane attachments
WO2005111057A2 (en) 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP2330208B1 (en) 2004-05-24 2017-10-18 Midatech Ltd. Nanoparticles comprising RNA ligands
GB0411537D0 (en) 2004-05-24 2004-06-23 Midatech Ltd Nanoparticles comprising rna ligands
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
JP2008501807A (ja) 2004-06-08 2008-01-24 コーリー ファーマシューティカル ゲーエムベーハー 抗原ならびに免疫活性化アゴニストおよび免疫活性化アンタゴニストのための担体基本骨格としての無塩基オリゴヌクレオチド
EP1604669A1 (en) 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
HUE036894T2 (hu) 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US20060147456A1 (en) 2004-07-20 2006-07-06 Serge Lebecque Induction of apoptosis in toll-like receptor expressing tumor cells
WO2006012695A1 (en) 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US20060083781A1 (en) 2004-10-14 2006-04-20 Shastri V P Functionalized solid lipid nanoparticles and methods of making and using same
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
CA2586913A1 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
EP1829887B1 (en) 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
EP2007421A2 (en) 2005-03-04 2008-12-31 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients.
US20070065359A1 (en) 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
WO2006110350A2 (en) 2005-03-29 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Method of fabricating lipid bilayer membranes on solid supports
DE102005016873A1 (de) 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
EP1880019A1 (en) 2005-05-12 2008-01-23 Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University Self-assembled nucleic acid nanoarrays and uses therefor
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
CN101268101A (zh) 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP5481068B2 (ja) 2005-08-31 2014-04-23 アメリカ合衆国 ＣｐＧオリゴデオキシヌクレオチドによって誘発される免疫応答を変化させる方法
WO2007047455A2 (en) 2005-10-13 2007-04-26 Northwestern University Colorimetric screening of dna binding/intercalating agents with gold nanoparticle probes
US20070093439A1 (en) 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
FR2892819B1 (fr) 2005-10-28 2008-02-01 Centre Nat Rech Scient Nanoparticules a luminescence persistance pour leur utilisation en tant qu'agent de diagnostic destine a l'imagerie optique in vivo
US7776834B2 (en) 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1942945B1 (en) 2005-11-07 2011-10-19 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2009514525A (ja) 2005-11-07 2009-04-09 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性
US20100003287A1 (en) 2005-12-01 2010-01-07 The Provost, Fellows And Scholars Of The Coll. Of The Holy And Undivided Trinity Of Queen Elizabeth Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases
JP5122474B2 (ja) 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
US20090317802A1 (en) 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CA2632940A1 (en) 2005-12-20 2007-07-05 Idera Pharmaceuticals, Inc. Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
JP2009520502A (ja) 2005-12-20 2009-05-28 イデラ ファーマシューティカルズ インコーポレイテッド Ｃｇジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
EP1991678B2 (en) 2006-02-15 2020-07-15 Rechtsanwalt Thomas Beck Compositions and methods for oligonucleotide formulations
EP1820804A1 (en) 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipidated oligonucleotides
US8361494B2 (en) 2006-03-10 2013-01-29 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
US20090191185A1 (en) 2006-04-26 2009-07-30 The Uab Research Foundation Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
WO2007131495A2 (de) 2006-05-11 2007-11-22 Mologen Ag Multimer zur immunstimulation
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2008097328A2 (en) 2006-06-23 2008-08-14 Northwestern University Asymmetric functionalized nanoparticles and methods of use
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
JP2010507361A (ja) * 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP2010500375A (ja) 2006-08-08 2010-01-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 活性剤の多段階送達
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20100099858A1 (en) 2006-09-28 2010-04-22 Mirkin Chad A Maximizing Oligonucleotide Loading on Gold Nanoparticle
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US7976743B2 (en) 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
WO2008073959A2 (en) 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of tlr9
US20080181928A1 (en) 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8415461B2 (en) 2007-01-19 2013-04-09 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and functionalized lipid vesicles including the same
WO2008089771A1 (en) 2007-01-24 2008-07-31 Syddansk Universitet Dna controlled assembly of lipid membranes
KR101488800B1 (ko) 2007-02-09 2015-02-04 노오쓰웨스턴 유니버시티 세포내 타겟 검출용 입자
US20100167290A1 (en) 2007-02-27 2010-07-01 Robert Elghanian Molecule attachment to nanoparticles
AR065865A1 (es) 2007-03-30 2009-07-08 Hirofumi Takeuchi Liposoma para la administracion pulmonar para controlar el suministro de la droga
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
JP5479319B2 (ja) 2007-04-12 2014-04-23 バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー ブイ式懸濁液分画システム
PT2170353E (pt) 2007-05-18 2015-09-16 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
CA3055145A1 (en) 2007-05-30 2008-12-11 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8278043B2 (en) 2007-06-05 2012-10-02 Melica Hb Methods and materials related to grey alleles
CA2692161C (en) 2007-07-09 2015-09-29 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds
CA2731399A1 (en) 2007-07-23 2009-01-29 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
CA2693266C (en) 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
AU2008288241B2 (en) * 2007-08-13 2011-12-01 Zoetis Belgium S.A. RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
US8853375B2 (en) 2007-08-15 2014-10-07 Idera Pharmaceuticals, Inc. Toll like receptor modulators
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2200639B1 (en) 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
US8399005B2 (en) 2007-10-12 2013-03-19 University Of North Carolina At Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
CN101980712B (zh) 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
EP2058397A1 (de) 2007-11-07 2009-05-13 Mologen AG Multimeres Assemblat zur Immunstimulation
US20100285111A1 (en) 2007-11-09 2010-11-11 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
US20110020242A1 (en) 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
US8741337B2 (en) 2008-01-04 2014-06-03 Aveka, Inc. Encapsulation of oxidatively unstable compounds
AU2009215795A1 (en) 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
EP2257306B1 (en) 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
CN102065848A (zh) 2008-04-21 2011-05-18 3M创新有限公司 释放一氧化一氮的组合物、装置和方法
MX2010011680A (es) 2008-04-25 2011-05-03 Univ Northwestern Nanoestructuras adecuadas para secuestrar colesterol y otras moleculas.
CA2723226A1 (en) 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
US8063131B2 (en) 2008-06-18 2011-11-22 University Of Washington Nanoparticle-amphipol complexes for nucleic acid intracellular delivery and imaging
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
MX2011001050A (es) 2008-07-28 2011-03-15 Idera Pharmaceuticals Inc Modulacion de la expresion del receptor 9 tipo larga distancia por oligonucleotidos antisentido.
US20100047188A1 (en) 2008-08-04 2010-02-25 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 8 expression by antisense oligonucleotides
KR20110044277A (ko) 2008-08-04 2011-04-28 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 톨-유사 수용체 ３ 발현의 조절
MX2011001422A (es) 2008-08-08 2011-03-15 Idera Pharmaceuticals Inc Modulacion de expresion de gen de respuesta primaria de diferenciacion mieloide 88 por oligonucleotidos antisentido.
EP2328613A1 (en) 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccine
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
NZ601345A (en) 2008-10-16 2014-05-30 Univ Dalhousie Combination adjuvant formulation
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
US8574582B2 (en) 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
US20110223257A1 (en) 2008-11-17 2011-09-15 Enzon Pharmaceuticals, Inc. Releasable fusogenic lipids for nucleic acids delivery systems
CN106955360A (zh) 2008-11-24 2017-07-18 西北大学 多价rna纳米颗粒组合物
US20120093914A1 (en) * 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
WO2010078516A2 (en) 2009-01-01 2010-07-08 Cornell University Multifunctional nucleic acid nano-structures
JP5801205B2 (ja) 2009-01-08 2015-10-28 ノースウェスタン ユニバーシティ 多価オリゴヌクレオチド修飾ナノ粒子コンジュゲートによる細菌タンパク質産生の阻害
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20120040004A1 (en) 2009-01-28 2012-02-16 Region Midtjylland Treatment of radiation-induced fibrosis
BRPI1008063A2 (pt) 2009-01-30 2015-08-25 Idera Pharmaceuticals Inc Agonistas sinteticas de tlr9
WO2010091293A1 (en) 2009-02-06 2010-08-12 The Regents Of The University Of California Plasmonic system for detecting binding of biological molecules
AR070368A2 (es) 2009-02-12 2010-03-31 Smithkline Beecham Biolog Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
CN102625842A (zh) 2009-03-13 2012-08-01 艾根股份有限公司 用于输送生物活性rna的组合物和方法
CN108451968A (zh) 2009-04-15 2018-08-28 西北大学 寡核苷酸功能化的纳米颗粒的递送
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
KR101626060B1 (ko) 2009-06-18 2016-05-31 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
WO2011017382A2 (en) * 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US20120277283A1 (en) 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
WO2011017690A2 (en) 2009-08-07 2011-02-10 Northwestern University Intracellular delivery of contrast agents with functionalized nanoparticles
HRP20150566T1 (hr) 2009-08-27 2015-07-17 Idera Pharmaceuticals, Inc. Kompozicija za inhibiciju ekspresije gena i njegova upotreba
US20120244230A1 (en) 2009-09-01 2012-09-27 Massachusetts Institute Of Technology Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
CA2772660A1 (en) 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
KR101132626B1 (ko) 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
SG181823A1 (en) 2009-12-23 2012-07-30 Max Planck Gesellschaft Influenza targets
WO2011079290A1 (en) 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2399608B1 (en) 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy
US20130101512A1 (en) 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
US8747869B2 (en) 2010-03-19 2014-06-10 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
KR101198715B1 (ko) 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
JP6034285B2 (ja) 2010-05-28 2016-11-30 ゾエティス・ベルジャム・エス・アー 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
US20130089614A1 (en) 2010-06-14 2013-04-11 Xuefeng Zhang Magnetic Nanoparticles and Uses Thereof
BR112012032240A2 (pt) 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
EP3269811B1 (en) 2010-07-28 2020-10-07 Advanced Innovation Development Co. Ltd. Nucleic acid having adjuvant activity and use thereof
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
EP2618846A1 (en) 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US20130095039A1 (en) 2010-09-30 2013-04-18 The Board Of Trustees Of The University Of Illinois Nucleic acid-mediated shape control of nanoparticles
AR083561A1 (es) 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
US8486908B2 (en) 2010-11-19 2013-07-16 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
GB201021873D0 (en) 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2822350T3 (es) 2011-04-28 2021-04-30 Platform Brightworks Two Ltd Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
JP6049712B2 (ja) * 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
EP2548571A1 (en) 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
CA2848359A1 (en) 2011-09-11 2013-03-14 Aurasense, Llc Cellular uptake control systems
EP2755692B1 (en) 2011-09-14 2020-11-25 Northwestern University Nanoconjugates able to cross the blood-brain barrier
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
JP2014527983A (ja) 2011-09-19 2014-10-23 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
JP2015509085A (ja) 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
ES2731524T3 (es) * 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
AU2013262972A1 (en) 2012-05-16 2014-12-11 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
EP2852381B1 (en) 2012-05-23 2020-10-07 The Ohio State University Lipid nanoparticle compositions and methods of making and methods of using the same
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
US9095625B2 (en) 2012-08-31 2015-08-04 University Of Massachusetts Graft-copolymer stabilized metal nanoparticles
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2014123935A1 (en) 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers
US9968673B2 (en) 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
CN103212089B (zh) 2013-04-07 2016-08-24 中国科学院上海应用物理研究所 一种碳纳米材料-免疫刺激序列复合物的制备方法及其应用
US9617544B2 (en) 2013-04-11 2017-04-11 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of siRNA
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CA2919273A1 (en) * 2013-07-25 2015-01-29 Exicure, Inc. Spherical nucleic acid-based constructs as immunoregulatory agents
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
EP3033422A4 (en) 2013-08-16 2017-08-02 Rana Therapeutics Inc. Oligonucleotides targeting euchromatin regions of genes
EP3521431A1 (en) 2013-09-25 2019-08-07 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
KR101465365B1 (ko) 2013-10-15 2014-11-25 성균관대학교산학협력단 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법
WO2015077657A2 (en) 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof
MX389323B (es) * 2013-12-03 2025-03-20 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10619210B2 (en) 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
WO2015128461A1 (en) 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
EP3129391A4 (en) 2014-04-03 2017-12-20 Exicure, Inc. Self assembling nucleic acid nanostructures
EP3128008B1 (en) 2014-04-04 2024-05-29 Bioneer Corporation Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10278984B2 (en) 2014-05-02 2019-05-07 Nitor Therapeutics Guanosine as an immune potentiator mediated through toll receptors
US10434064B2 (en) * 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US9919058B2 (en) 2014-07-15 2018-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer
CN107074767A (zh) 2014-08-20 2017-08-18 西北大学 用于反义基因调节的生物相容的无限配位聚合物纳米颗粒–核酸缀合物
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗ｔｎｆ化合物
EP3247796A4 (en) 2015-01-14 2018-07-11 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2016134104A1 (en) 2015-02-18 2016-08-25 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
MX391074B (es) 2015-05-19 2025-03-21 Univ Yale Composiciones para el tratamiento de condiciones patológicas de calcificación y sus métodos de uso.
EP3322407A4 (en) 2015-07-14 2019-07-10 Exicure, Inc. RELOCATION OF LIPID COMPLEXES IN CELLS INDUCED BY SPINICAL NUCLEIC ACIDS (SNA)
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
WO2017136467A1 (en) 2016-02-01 2017-08-10 Exicure, Inc. Surface functionaliztion of liposomes and liposomal spherical nucleic acids (snas)
US20170240960A1 (en) * 2016-02-24 2017-08-24 Aurasense, Llc Spherical nucleic acids (sna) flare based fluorescence in situ hybridization
US20190142739A1 (en) 2016-04-19 2019-05-16 Exicure, Inc. Topical administration of therapeutic agents and oligonucleotide formulations
CA3023445A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Spherical nucleic acid tlr9 agonists
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
CA3023449A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Tlr9-targeted spherical nucleic acids having potent antitumor activity
WO2018053508A1 (en) 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US20200248183A1 (en) 2017-04-03 2020-08-06 Subbarao Nallagatla Tlr9-targeted spherical nucleic acids having potent antitumor activity
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2019168558A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
WO2019169203A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
US20220088059A1 (en) 2019-02-12 2022-03-24 Exicure Operating Company Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy
WO2020219985A1 (en) 2019-04-26 2020-10-29 Exicure, Inc. Administration of spherical nucleic acids for ophthalmological uses

Also Published As

Publication number Publication date
JP6581604B2 (ja) 2019-09-25
US11123294B2 (en) 2021-09-21
US20200069587A1 (en) 2020-03-05
KR102290205B1 (ko) 2021-08-20
US11957788B2 (en) 2024-04-16
PL3164113T3 (pl) 2019-09-30
AU2015269412B2 (en) 2020-03-12
TR201908550T4 (tr) 2019-07-22
CA2953216A1 (en) 2015-12-10
CN106535876B (zh) 2020-09-11
EP3164113B1 (en) 2019-03-27
US20220257512A1 (en) 2022-08-18
AU2015269412A1 (en) 2016-12-22
US20170157048A1 (en) 2017-06-08
KR20170005499A (ko) 2017-01-13
WO2015187966A1 (en) 2015-12-10
CA2953216C (en) 2020-12-22
JP2017524658A (ja) 2017-08-31
CN106535876A (zh) 2017-03-22
US10434064B2 (en) 2019-10-08
EP3164113A1 (en) 2017-05-10
EP3508198A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
ES2725948T3 (es) Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
ES2750608T3 (es) Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
US20170175121A1 (en) Self assembling nucleic acid nanostructures
CN101874112B (zh) 特别是作为免疫刺激剂/佐剂的式(I)：GlXmGn或式(II)：ClXmCn的核酸
ES2486298T3 (es) Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados
WO2015013675A9 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
US20200297867A1 (en) Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
ES2544484T3 (es) Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante
JP2012517226A (ja) Ｔｌｒ７の合成ｒｎａベースのアゴニスト
EP3301179B1 (en) Immunostimulating oligonucleotide complex
WO2016149323A1 (en) Immunomodulatory spherical nucleic acids